A Unique Antibiotic Pipeline for Today and Tomorrow

Spero Therapeutics’ experienced and dedicated leadership team is working
tirelessly to advance our unique portfolio of novel drug candidates
designed to combat Gram-negative bacterial infections through clinical
development and regulatory approval.

Programs Designed to Address Unmet Needs in Infectious Diseases

Spero Therapeutics’ antibiotic pipeline is focused on areas for which the unmet medical need is greatest, the biological rationale for treatment is clear, and for which there are few approved therapies, or where the standard of care is suboptimal.

Our pipeline of anti-infective agents is one of the most unique in the industry and consists of four complementary product candidates, including:

  • SPR994 Oral Gram-Negative Program is a first in class oral carbapenem that has demonstrated potent in vitro and in vivo activity against a wide variety of Gram-negative bacterial infections, including those harboring drug-resistant extended-spectrum beta-lactamases (ESBLs).
  • SPR741 IV Potentiator Platform is our technology designed to treat serious and life-threatening multi-drug resistant Gram-negative pathogens, such as Enterobacteriaceae, with combination therapies.

The following table illustrates our product candidates, their status, and anticipated milestones for ongoing development.

Product Candidate Pipeline and Anticipated Milestones


Information as of September 5, 2018

This chart contains forward-looking statements. Our planned development activities and anticipated milestones are based on our current assumptions, estimates and plans, which may change.

  • Investors

    Contact us to learn about investment opportunities.

    Investment opportunities >
  • Careers

    Join a passionate team that pushes the limits in finding innovative therapies to help patients. Named one of Boston’s Best Places to Work.

    Career opportunities >
  • Partners

    Our strategic partnerships foster mutually beneficial alliances that advance medicine to improve patient lives.

    Partnership opportunities >